Allergan Medical Institute - Discover the Latest Learning Resources on AMI Online

Designed to try^†,*, Boey^® offers rapid-onset,^†,‡ short-duration^§ results for
patients interested in neurotoxin treatment but hesitant to commit to
longer-lasting results.^1,‖

Ready to explore Boey^® further? Discover new AMI Online resources
to deepen your knowledge of Boey^® and its use in practice, including:

Introducing Boey^® Module

Access a practical training module exploring Boey^®’s clinical profile,
supporting evidence, patient identification strategies, treatment
considerations, and its role within the aesthetic treatment journey.

By the end of this activity, you’ll be able to:

Describe Boey^®’s
mechanism of action,
clinical profile,
and approved
indication.

Apply structured
consultation and
assessment
techniques for
treatment planning.

Discuss treatment
considerations,
follow-up, and
expectation
management.

Evaluate Boey^®’s role
in the aesthetic journey,
including transitions to
BOTOX COSMETIC^®
when appropriate.

Boey^® Reconstitution and Injection Guide

Download a comprehensive guide to learn more about the on-label
reconstitution, dosing, injection technique, and administration of
Boey^® for moderate-to-severe glabellar lines.

KEY TAKEAWAYS

Describe Boey^®’s key features and approved indication.

Identify recommended dosing, injection patterns,
and administration techniques for glabellar lines.

Apply best practices for storage, preparation,
and post-treatment patient care.

Coming Soon: Webinar Recording

Missed the live event?

You can watch Unlock a New Era of Neurotoxin: Introducing Boey^®
to hear from internationally renowned speakers exploring the
science behind Boey^®, supporting clinical evidence, and practical
considerations for patient selection and treatment planning.

Watch the webinar to:

Explore the opportunities shaping the future of aesthetic neurotoxin treatments.

Discover the science and clinical evidence supporting Boey^®.

Learn about considerations for patient selection and treatment planning – and more!

Coming Soon:
A New Way to Learn
with AMI Tutor.

Looking for a more interactive Boey^®
learning experience?

AMI Tutor is a new AMI Online offering
featuring live, small-group sessions led
by Allergan Aesthetics-selected clinical
educators, with opportunities for discussion,
questions, and practical clinical learning.

More exciting details are on the way!

This is our future, let’s shape it together.

Allergan Medical Institute:
empowering excellence in aesthetics.

CA-TRENI-260052

You received this email because you signed up to receive communications from Allergan Aesthetics, and AbbVie Corporation division (“AbbVie”). If you no longer wish to receive communications from Allergan Aesthetics, you may withdraw your consent at any time by emailing MKH-Customer-OptOut@allergan.com.

^*Boey^® is a botulinum neurotoxin serotype E (BoNT/E) developed for the treatment of facial wrinkles. It
has a distinct pharmacological profile, with onset of effect observed within hours after injection and a
duration of response that lasted approximately 2–3 weeks. No other BoNT/E product is currently
marketed.

^†In two randomised, multicentre, double-blind, placebo-controlled studies (M21-500 and M21-508), 947 patients were treated with Boey^® 700 U total dose or placebo. The multi-component efficacy measure (treatment effect) was defined as the percentage of subjects achieving a ≥2-grade improvement from baseline in glabellar line severity at maximum frown based on both the investigator and subject FWS assessment using the 4-point FWS (0=none, 1=mild, 2=moderate, 3=severe) at Day 7. In the ITT population, 60% (n=289/482; M21-500) and 65.7% (n=149/227; M21-508) of patients treated with Boey^® achieved a ≥2-grade improvement in frown line severity at maximum frown at Day 7 (assessed by both
the investigator and the subject), p<0.0001 vs. placebo. Adverse drug reactions in the pivotal studies were eyelid ptosis (uncommon), brow ptosis (uncommon) and Mephisto sign (rare).¹

^‡Boey^® 700 U had an onset of effect observed appearing as early as 8 hours after injection with Boey^® 700 U in both pivotal studies M21-500 and M21-508. At Hour 8, 7.1% patients (n=34/482; p=0.0006 vs. placebo) in M21-500 and 5.3% patients (n=12/227) in M21-508 treated with Boey^® 700 U showed ≥2
grade improvement in frown lines at maximum frown from baseline in the ITT population based on both
the investigator and subject FWS assessment. The peak effect was seen at Day 7 in both studies.^1,3,4

^§Following treatment with Boey^® 700 U in two randomised, placebo-controlled studies (M21-500 and
M21-508), patients in the ITT population who achieved ≥2-grade improvement in frown lines at maximum
frown at Day 7 based on both the investigator and subject FWS assessment returned to baseline severity
in approximately 21 days after administration (2.7% n=13.1/482, p=0.0385 vs. placebo for M21-500; 1.4%
n=3/227 for M21-508).^3,4

^‖Boey^® is indicated in adult patients for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity.¹

1. Boey^® Product Monograph AbbVie Corporation, QC, Canada June 2026.
2. George R et al. Safety and efficacy of trenibotulinumtoxinE for treating glabellar lines in toxin naïve participants: Results from a multicenter phase 3 study. ASDS 2025, Chicago, IL. REF-143817.
3. Allergan Aesthetics. Data on File. REF-146959. ABVRRTI82840 M21-500 Clinical Data (FDA) for
AGN-151586: Safety & Efficacy. March 2026.
4. Allergan Aesthetics. Data on File. REF-146953. ABVRRTI82752 M21-508 Clinical Data (FDA) for
AGN-151586: Safety & Efficacy. March 2026.